In today's news, updated data on an experimental breast cancer drug called trastuzumab emtansine, or T-DM1, shows better survival (by five months) than a standard mix of two other drugs for metastatic breast cancer patients.  We've talked often on this blog about the importance of taking these incremental steps toward finding the best cocktail of […]